Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 4

1.

Phase I trial of pelvic nodal dose escalation with hypofractionated IMRT for high-risk prostate cancer.

Adkison JB, McHaffie DR, Bentzen SM, Patel RR, Khuntia D, Petereit DG, Hong TS, Tomé W, Ritter MA.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):184-90. doi: 10.1016/j.ijrobp.2010.09.018. Epub 2010 Dec 14.

2.

Late toxicity rates following definitive radiotherapy for prostate cancer.

Ohri N, Dicker AP, Showalter TN.

Can J Urol. 2012 Aug;19(4):6373-80. Review.

3.

Salvage reirradiation for locoregional failure after radiation therapy for prostate cancer: who, when, where and how?

Créhange G, Roach M 3rd, Martin E, Cormier L, Peiffert D, Cochet A, Chapet O, Supiot S, Cosset JM, Bolla M, Chung HT.

Cancer Radiother. 2014 Oct;18(5-6):524-34. doi: 10.1016/j.canrad.2014.07.153. Epub 2014 Sep 2. Review. Erratum in: Cancer Radiother. 2014 Dec;18(8):806.

PMID:
25192626
4.

Fiducial marker guided prostate radiotherapy: a review.

O'Neill AG, Jain S, Hounsell AR, O'Sullivan JM.

Br J Radiol. 2016 Dec;89(1068):20160296. Epub 2016 Sep 23. Review.

Supplemental Content

Support Center